{"id":"budesonide-formoterol-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Nervousness/anxiety"},{"rate":null,"effect":"Muscle cramps"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Budesonide is an inhaled corticosteroid that suppresses inflammatory responses in the airways by binding glucocorticoid receptors, reducing mucus production and airway edema. Formoterol is a long-acting beta-2 adrenergic agonist (LABA) that binds beta-2 receptors on airway smooth muscle, causing bronchodilation and improved airflow. Together, they provide both anti-inflammatory and bronchodilatory effects for sustained asthma and COPD control.","oneSentence":"Budesonide-formoterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle to improve breathing.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:35.056Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance and reliever therapy"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT06712563","phase":"","title":"Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2000},{"nctId":"NCT07073950","phase":"PHASE4","title":"A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":"Chronic Obstructive Pulmonary Disease, Hyperinflation","enrollment":56},{"nctId":"NCT06531798","phase":"PHASE4","title":"Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-19","conditions":"Moderate to Severe COPD","enrollment":150},{"nctId":"NCT05862545","phase":"","title":"Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-06-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":250},{"nctId":"NCT07069829","phase":"","title":"Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1400},{"nctId":"NCT07426458","phase":"PHASE4","title":"Ventilation and Perfusion in Asthmatics","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-04","conditions":"Asthma","enrollment":40},{"nctId":"NCT07433569","phase":"PHASE1","title":"A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-05","conditions":"Asthma","enrollment":12},{"nctId":"NCT06473779","phase":"PHASE3","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Severe Asthma","enrollment":326},{"nctId":"NCT06067828","phase":"PHASE3","title":"A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-10-24","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":171},{"nctId":"NCT06905483","phase":"PHASE4","title":"Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2025-04-01","conditions":"COPD, Chronic Obstructive Pulmonary Disease (COPD), Small Airway Disease","enrollment":22},{"nctId":"NCT07372573","phase":"NA","title":"Pressurized Meter Dose Inhaler V/S Dry Powder Inhaler","status":"NOT_YET_RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2026-02-01","conditions":"Asthma (Diagnosis)","enrollment":210},{"nctId":"NCT06429475","phase":"PHASE3","title":"Anti-Inflammatory Reliever South Africa","status":"RECRUITING","sponsor":"University of KwaZulu","startDate":"2024-06-06","conditions":"Asthma","enrollment":1038},{"nctId":"NCT07329946","phase":"NA","title":"Immuno-inflammatory Response of Erdosteine in COPD","status":"NOT_YET_RECRUITING","sponsor":"Pierachille Santus, MD, PhD","startDate":"2026-02-28","conditions":"COPD","enrollment":30},{"nctId":"NCT07318350","phase":"PHASE3","title":"Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-10","conditions":"Moderate Asthma","enrollment":174},{"nctId":"NCT06368427","phase":"","title":"Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-30","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":10},{"nctId":"NCT05735431","phase":"PHASE3","title":"Non-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-06","conditions":"Moderate Asthma","enrollment":""},{"nctId":"NCT06110403","phase":"PHASE1, PHASE2","title":"Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2023-09-29","conditions":"Copd","enrollment":35},{"nctId":"NCT07052942","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care (Full Study)","status":"RECRUITING","sponsor":"DARTNet Institute","startDate":"2025-08-01","conditions":"Asthma, Asthma Attack, Asthma Exacerbations","enrollment":3200},{"nctId":"NCT06590740","phase":"PHASE4","title":"Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-10-18","conditions":"Cough-Variant Asthma","enrollment":1000},{"nctId":"NCT05689983","phase":"PHASE1, PHASE2","title":"Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-04-01","conditions":"Asthma in Children, Nonadherence, Medication","enrollment":40},{"nctId":"NCT05111262","phase":"PHASE1, PHASE2","title":"Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2021-12-16","conditions":"Asthma, Nonadherence, Medication","enrollment":60},{"nctId":"NCT05477108","phase":"PHASE1","title":"Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT06075095","phase":"PHASE3","title":"A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-01-11","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":297},{"nctId":"NCT06744374","phase":"","title":"A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-02-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22369},{"nctId":"NCT05569421","phase":"PHASE1","title":"A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-10-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":108},{"nctId":"NCT06340581","phase":"PHASE1","title":"A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2024-10-17","conditions":"Healthy","enrollment":""},{"nctId":"NCT06297668","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-04-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":42},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":"Atopic Rhinitis, Atopic Asthma","enrollment":200},{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT05213611","phase":"","title":"REported Outcomes in COPD With Trixeo in Real worlD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-08-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":150},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT05311306","phase":"","title":"REported Outcomes in COPD With Trixeo in Real worlD in Germany","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-03-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":475},{"nctId":"NCT06895460","phase":"PHASE3","title":"A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-06-20","conditions":"Bronchial Asthma","enrollment":198},{"nctId":"NCT06723756","phase":"PHASE1","title":"A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-01-23","conditions":"Healthy Participants","enrollment":105},{"nctId":"NCT06272370","phase":"PHASE4","title":"Individualizing Treatment for Asthma in Primary Care","status":"COMPLETED","sponsor":"DARTNet Institute","startDate":"2024-02-01","conditions":"Asthma, Bronchial Diseases, Respiratory Tract Infections","enrollment":103},{"nctId":"NCT05915182","phase":"","title":"Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-07-21","conditions":"Pulmonary Disease, Chronic Obstructive (COPD)","enrollment":218},{"nctId":"NCT05831566","phase":"PHASE3","title":"Expertise Asthma COPD Program with Digital Support","status":"RECRUITING","sponsor":"Franciscus Gasthuis","startDate":"2023-01-31","conditions":"Asthma","enrollment":138},{"nctId":"NCT06597682","phase":"NA","title":"Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-03","conditions":"Post-acute Sequelae of SARS-COV-2 Infection","enrollment":632},{"nctId":"NCT06844175","phase":"","title":"Early Screening of Young COPD and Pre-COPD","status":"NOT_YET_RECRUITING","sponsor":"yanmengkang","startDate":"2025-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":100},{"nctId":"NCT04233190","phase":"PHASE3","title":"A Multicenter, Randomized, Parallel, Two-period, Non-inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2023-04-19","conditions":"Asthma Copd","enrollment":472},{"nctId":"NCT03924635","phase":"PHASE4","title":"An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-01","conditions":"Airway Inflammation, Asthma","enrollment":42},{"nctId":"NCT06772454","phase":"","title":"To Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD)","status":"RECRUITING","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2023-01-01","conditions":"Lung Cancer Squamous Cell, COPD","enrollment":60},{"nctId":"NCT04159519","phase":"PHASE4","title":"A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-07-27","conditions":"Asthma, Severe Eosinophilic Asthma","enrollment":170},{"nctId":"NCT06514144","phase":"","title":"Exacerbations Among Patients Receiving Breztri (EROS Study)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-10-01","conditions":"Pulmonary Disease, Chronic Obstructive, Retrospective Studies","enrollment":2409},{"nctId":"NCT06573164","phase":"","title":"Allergic Rhinitis With/Without Asthma: Pre- and Post-Qipian Analysis","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-01-01","conditions":"Rhinitis, Allergic, Asthma","enrollment":60},{"nctId":"NCT06571942","phase":"PHASE4","title":"Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure","status":"RECRUITING","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2023-11-15","conditions":"COPD Bronchitis, Pollution Related Respiratory Disorder","enrollment":128},{"nctId":"NCT06568445","phase":"PHASE4","title":"Maintenance at Initial Treatment With Sequential Anti-Inflammation Reliever Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2024-08-12","conditions":"Bronchial Asthma","enrollment":90},{"nctId":"NCT02062463","phase":"PHASE3","title":"Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-05-28","conditions":"Asthma","enrollment":485},{"nctId":"NCT06317428","phase":"","title":"NT-proBNP Levels During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.","status":"RECRUITING","sponsor":"Istituto Nazionale di Ricovero e Cura per Anziani","startDate":"2022-06-28","conditions":"COPD","enrollment":29},{"nctId":"NCT05970263","phase":"PHASE4","title":"IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2024-01-19","conditions":"COPD","enrollment":""},{"nctId":"NCT01803555","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07-04","conditions":"Asthma","enrollment":605},{"nctId":"NCT04835961","phase":"","title":"AdditioN of Fixed Dose Combination (FDC) Of Budesonide/Formoterol Via Elpenhaler® Device in Greek Patients With asThma accΟrding to Standard Clinical Practice.","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2021-05-01","conditions":"Asthma","enrollment":1037},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT05322707","phase":"PHASE3","title":"BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2022-04-15","conditions":"Asthma","enrollment":1485},{"nctId":"NCT04705727","phase":"PHASE3","title":"Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation","status":"TERMINATED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2021-08-23","conditions":"Asthma in Children","enrollment":102},{"nctId":"NCT04600505","phase":"PHASE1","title":"A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-10-19","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":47},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT05596721","phase":"PHASE4","title":"Azithromycin Treatment for Non-eosinophilic Chest Tightness Variant Asthma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-01-01","conditions":"Asthma, Chest Syndrome, Azithromycin","enrollment":248},{"nctId":"NCT03033758","phase":"","title":"Evaluation of the Effectiveness and Quality of Life With the Administration of the Fixed Combination of Budesonide Formoterol in Greek Patients With Asthma During Routine Clinical Practice.","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2017-02-02","conditions":"Asthma, Quality of Life","enrollment":980},{"nctId":"NCT03015259","phase":"PHASE3","title":"Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients","status":"COMPLETED","sponsor":"Kindeva Drug Delivery","startDate":"2016-12-29","conditions":"Asthma","enrollment":1762},{"nctId":"NCT03691961","phase":"NA","title":"Corticosteroids/β2-agonists in Hair in Asthmatic Patients (CorticHair)","status":"UNKNOWN","sponsor":"Hopital Foch","startDate":"2018-09-20","conditions":"Asthma","enrollment":24},{"nctId":"NCT04191434","phase":"PHASE3","title":"Efficacy and Safety of Flamboyant 125/12 Association in the Treatment of Adults With Moderate Asthma","status":"UNKNOWN","sponsor":"EMS","startDate":"2022-07-22","conditions":"Asthma","enrollment":134},{"nctId":"NCT04191447","phase":"PHASE3","title":"Efficacy and Safety of Flamboyant 200/12 Association in the Treatment of Adults With Severe Asthma","status":"UNKNOWN","sponsor":"EMS","startDate":"2022-07-22","conditions":"Asthma","enrollment":134},{"nctId":"NCT04203472","phase":"NA","title":"Optimal Type of Inhaler in Cough Variant- or Cough Predominant Asthma","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2019-01-20","conditions":"Asthma, Cough Variant Asthma","enrollment":22},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT03083067","phase":"NA","title":"Salvational Intervention for Reducing AECOPD Under Severe Air Pollution","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2017-03-20","conditions":"COPD Exacerbation, Air Pollution","enrollment":402},{"nctId":"NCT04078126","phase":"PHASE3","title":"Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-09-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":35},{"nctId":"NCT02237508","phase":"PHASE1","title":"A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2014-09","conditions":"Asthma","enrollment":90},{"nctId":"NCT02631941","phase":"PHASE1","title":"Clinical Study to Evaluate Z7200 Pharmacokinetics Profile","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2016-01","conditions":"Asthma","enrollment":91},{"nctId":"NCT02227394","phase":"PHASE2","title":"Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2014-08","conditions":"Asthma, Asthma Chronic, Asthma Bronchial","enrollment":20},{"nctId":"NCT02384577","phase":"","title":"Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment","status":"COMPLETED","sponsor":"Teva Pharma GmbH","startDate":"2014-07","conditions":"Patient Satisfaction","enrollment":4034},{"nctId":"NCT03468790","phase":"PHASE3","title":"Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-05-09","conditions":"Asthma, Allergic","enrollment":393},{"nctId":"NCT04179461","phase":"PHASE2","title":"Personalized Treatment Algorithms for Difficult-to-treat Asthma","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-03-16","conditions":"Asthma in Children","enrollment":21},{"nctId":"NCT03219866","phase":"PHASE4","title":"Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2017-10-03","conditions":"COPD, COPD Exacerbation","enrollment":40},{"nctId":"NCT03836677","phase":"PHASE3","title":"A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-02-26","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":23},{"nctId":"NCT02465567","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-06-30","conditions":"COPD","enrollment":8588},{"nctId":"NCT03250182","phase":"PHASE1","title":"A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2017-08-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":30},{"nctId":"NCT03075267","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2017-04-17","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":96},{"nctId":"NCT04675463","phase":"NA","title":"The Effects of Inhaled Budesonide-formoterol-glycopyrronium in Moderate-to-severe COPD","status":"UNKNOWN","sponsor":"ShiYue Li","startDate":"2020-12-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":50},{"nctId":"NCT04607629","phase":"PHASE3","title":"An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2018-06-20","conditions":"Bronchial Asthma","enrollment":192},{"nctId":"NCT03114969","phase":"","title":"Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":450},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT04520230","phase":"PHASE4","title":"Three Treatment of Chronic Obstructive Pulmonary Disease Patients","status":"COMPLETED","sponsor":"Tanta University","startDate":"2014-10-31","conditions":"COPD","enrollment":45},{"nctId":"NCT00413387","phase":"PHASE3","title":"Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-09","conditions":"Bronchial Asthma","enrollment":219},{"nctId":"NCT04494321","phase":"PHASE1","title":"A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block","status":"COMPLETED","sponsor":"Intech Biopharm Ltd.","startDate":"2017-06-19","conditions":"Asthma, COPD","enrollment":99},{"nctId":"NCT03788395","phase":"PHASE4","title":"The Use of an Innovative Device for Therapeutic Adherence in Pediatric Asthma","status":"COMPLETED","sponsor":"Istituto per la Ricerca e l'Innovazione Biomedica","startDate":"2019-01-10","conditions":"Asthma","enrollment":18},{"nctId":"NCT04171180","phase":"PHASE4","title":"The Efficacy of Budesonide/Formoterol in Cough Variant Asthma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-01","conditions":"Cough Variant Asthma","enrollment":500},{"nctId":"NCT04331470","phase":"PHASE2, PHASE3","title":"Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19","status":"UNKNOWN","sponsor":"Fasa University of Medical Sciences","startDate":"2020-04-04","conditions":"COVID-19","enrollment":30},{"nctId":"NCT02495168","phase":"PHASE3","title":"Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2017-01-13","conditions":"Asthma","enrollment":1714},{"nctId":"NCT02224157","phase":"PHASE3","title":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-28","conditions":"Asthma","enrollment":4215},{"nctId":"NCT02149199","phase":"PHASE3","title":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-07-07","conditions":"Asthma","enrollment":3850},{"nctId":"NCT01794780","phase":"PHASE4","title":"A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-02-05","conditions":"COPD","enrollment":2229},{"nctId":"NCT02727660","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2016-04-29","conditions":"Chronic Obstructive Pulmonary Disorder","enrollment":1876},{"nctId":"NCT02766608","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2016-05-31","conditions":"Chronic Obstructive Pulmonary Disorder","enrollment":2389},{"nctId":"NCT02477397","phase":"PHASE3","title":"Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2015-05-01","conditions":"COPD","enrollment":201},{"nctId":"NCT01912872","phase":"PHASE4","title":"Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-11-11","conditions":"Severe IgE-mediated Asthma","enrollment":112},{"nctId":"NCT00996697","phase":"PHASE4","title":"Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2006-10","conditions":"COPD","enrollment":23},{"nctId":"NCT02446418","phase":"PHASE3","title":"A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-09","conditions":"Asthma","enrollment":423}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Budesonide 160 μg/formoterol 4.5 μg treatment"],"phase":"marketed","status":"active","brandName":"Budesonide-Formoterol treatment","genericName":"Budesonide-Formoterol treatment","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Budesonide-formoterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle to improve breathing. Used for Asthma maintenance and reliever therapy, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}